Financial Data and Key Metrics Changes - As of June 30, 2023, cash balance and short-term deposits were $30.7 million, down from $34.3 million as of December 31, 2022, primarily due to cash used in operating activities, partially offset by proceeds from PIPE financing [20] - Research and development expenses net were $3.8 million for Q2 2023, compared to $4.6 million for the same period in 2022, attributed to a reduction in workforce and deprioritization of certain activities [21] - Net loss for Q2 2023 was $6.4 million, an improvement from $7.5 million in Q2 2022 [23] - Net cash used in operating activities was $9.1 million for the first half of 2023, compared to $16.4 million for the same period in 2022 [23] Business Line Data and Key Metrics Changes - The BX004 program continues to show promise, with positive feedback from the cystic fibrosis (CF) community regarding its potential to treat life-threatening infections [5][8] - Patient screening for Part 2 of the Phase Ib/IIa study has been completed, with enrollment exceeding original estimates, indicating strong execution by the clinical operations team [14] Market Data and Key Metrics Changes - BX004 has received Fast Track designation from the FDA, recognizing its potential to address significant unmet medical needs in the CF community [15] - The company anticipates holding a meeting with the FDA to plan the next stage of BX004's clinical development, assuming positive results from the ongoing study [3] Company Strategy and Development Direction - The company aims to leverage the Fast Track designation to expedite the drug development process, including potential rolling submission and priority review for the Biologics License Application [16][17] - The focus remains on addressing the unmet medical needs of CF patients, particularly in treating Chronic Pseudomonas aeruginosa infections [24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress of the BX004 program and the positive reception from stakeholders in the CF community [5][14] - The company is preparing for discussions with regulatory authorities regarding future studies, contingent on the outcomes of Part 2 of the trial [34] Other Important Information - The company completed a $7.5 million private placement in May 2023 to support the BX004 program and other R&D activities [4] - The management highlighted the importance of gathering more data from the ongoing study to better prepare for future discussions with the FDA [36] Q&A Session Summary Question: What are the logistics around the delay in Part 2 data? - Management indicated that the delay is due to exceeding enrollment expectations and operational issues, but no endpoints have changed [32] Question: What is the wish list for upcoming discussions with regulatory authorities? - Management mentioned pursuing orphan breakthrough and accelerated approval, contingent on positive data from the ongoing studies [42] Question: How much data has been reviewed along the way for Part 2? - Management confirmed that they are blinded to the data and have not seen any results yet, but noted increased patient referrals and screening success [36] Question: Will there be a need for 6-month data before the end of Phase II meeting with the FDA? - Management indicated that they feel comfortable proceeding without needing 6-month data, given the FDA's acknowledgment of the safety of the modality [37]

[FORM 10-Q Filing Information](index=1&type=section&id=FORM%2010-Q%20Filing%20Information) This section provides details on BiomX Inc.'s Form 10-Q filing, including company classification, NYSE American listings, and outstanding common stock as of May 9, 2023 [Filing Details](index=1&type=section&id=Filing%20Details) BiomX Inc. filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, incorporated in Delaware with principal offices in Israel, and its securities are registered on the NYSE American - BiomX Inc. filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023[1](index=1&type=chunk) - The company's securities (Units, Common Stock, Warrants) are traded on the NYSE American under symbols PHGE.U, PHGE, and PHGE.WS, respectively[4](index=4&type=chunk) - BiomX Inc. is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company[5](index=5&type=chunk) [Outstanding Shares](index=2&type=section&id=Outstanding%20Shares) As of May 9, 2023, BiomX Inc. had 45,979,730 shares of common stock issued and outstanding - As of May 9, 2023, **45,979,730 shares of common stock**, par value $0.0001 per share, were issued and outstanding[6](index=6&type=chunk) [CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION](index=4&type=section&id=CAUTIONARY%20STATEMENT%20REGARDING%20FORWARD-LOOKING%20INFORMATION) This section details the nature of forward-looking statements and outlines key risks that could materially affect BiomX Inc.'s future results and financial condition [Forward-Looking Statements and Risks](index=4&type=section&id=Forward-Looking%20Statements%20and%20Risks) This section outlines the forward-looking statements within the report and highlights significant risks and uncertainties that could cause actual results to differ materially. Key risks include the ability to generate revenue and secure financing, unpredictable timing and cost of phage technology development, political and economic instability (including in Israel), regulatory approvals, patient enrollment in clinical trials, competition, intellectual property protection, and the impact of COVID-19 - Forward-looking statements include discussions on operations, cash flows, financial position, business strategy, clinical and pre-clinical development programs, and sufficiency of financial resources[10](index=10&type=chunk) - Key risks include the ability to generate revenues and raise sufficient financing, unpredictable timing and cost of phage technology development, political and economic instability (including in Israel), obtaining FDA acceptance for non-U.S. clinical trials, and the ability to enroll patients in clinical trials[10](index=10&type=chunk) - Other risks involve competition, intellectual property rights, reliance on third-party collaborators, ability to attract and retain key employees, and potential security breaches[13](index=13&type=chunk) [PART I - FINANCIAL INFORMATION](index=7&type=section&id=Part%20I.%20Financial%20Information) This section presents BiomX Inc.'s unaudited condensed consolidated financial statements and management's discussion and analysis for the quarter ended March 31, 2023 [Item 1. Financial Statements](index=7&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited condensed consolidated financial statements for BiomX Inc., including the balance sheets, statements of operations, statements of changes in stockholders' equity, and statements of cash flows, along with their accompanying notes. The financial data reflects the company's financial position and performance for the quarter ended March 31, 2023, compared to prior periods [Condensed Consolidated Balance Sheets](index=8&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheets provide a snapshot of BiomX Inc.'s assets, liabilities, and equity as of March 31, 2023, and December 31, 2022 | Metric (USD in thousands) | March 31, 2023 | December 31, 2022 | Change | % Change | | :------------------------ | :------------- | :---------------- | :----- | :------- | | Cash and cash equivalents | 29,346 | 31,332 | (1,986) | -6.34% | | Total current assets | 32,934 | 36,881 | (3,947) | -10.70% | | Total assets | 41,407 | 45,531 | (4,124) | -9.06% | | Total current liabilities | 10,200 | 7,939 | 2,261 | 28.48% | | Total non-current liabilities | 15,061 | 16,553 | (1,492) | -9.01% | | Total stockholders' equity | 16,146 | 21,039 | (4,893) | -23.26% | [Condensed Consolidated Statements of Operations](index=10&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) The statements of operations detail BiomX Inc.'s revenues, expenses, and net loss for the three months ended March 31, 2023, and 2022 | Metric (USD in thousands) | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | Change | % Change | | :------------------------ | :-------------------------------- | :-------------------------------- | :----- | :------- | | R&D expenses, net | 4,564 | 4,929 | (365) | -7.40% | | Amortization of intangible assets | - | 380 | (380) | -100.00% | | General and administrative expenses | 1,644 | 2,477 | (833) | -33.63% | | Operating loss | 6,208 | 7,786 | (1,578) | -20.27% | | Interest expenses | 565 | 461 | 104 | 22.56% | | Finance income, net | (327) | (87) | (240) | 275.86% | | Net loss | 6,361 | 8,169 | (1,808) | -22.13% | | Basic and diluted loss per share | 0.20 | 0.27 | (0.07) | -25.93% | [Condensed Consolidated Statements of Changes in Stockholders' Equity](index=11&type=section&id=Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders'%20Equity) This statement outlines changes in BiomX Inc.'s stockholders' equity, including common stock, additional paid-in capital, and accumulated deficit, for the period | Metric (USD in thousands) | As of January 1, 2023 | As of March 31, 2023 | | :------------------------ | :-------------------- | :------------------- | | Common Stock Shares | 29,976,582 | 33,176,073 | | Additional Paid-in Capital | 157,838 | 159,306 | | Accumulated Deficit | (136,801) | (143,162) | | Total Stockholders' Equity | 21,039 | 16,146 | - Issuance of Common Stock and warrants under Private Investment in Public Equity (PIPE) contributed **$1,293 thousand** (net of issuance costs) to additional paid-in capital during Q1 2023[29](index=29&type=chunk) - Net loss of **$6,361 thousand** significantly reduced stockholders' equity during Q1 2023[29](index=29&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=13&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) The cash flow statements categorize cash movements from operating, investing, and financing activities for the three months ended March 31, 2023, and 2022 | Metric (USD in thousands) | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | Change | % Change | | :------------------------ | :-------------------------------- | :-------------------------------- | :----- | :------- | | Net cash used in operating activities | (5,045) | (7,363) | 2,318 | -31.48% | | Net cash provided by (used in) investing activities | 1,990 | (10,020) | 12,010 | -120.06% | | Net cash provided by financing activities | 1,050 | 37 | 1,013 | 2737.84% | | Decrease in cash and cash equivalents and restricted cash | (2,005) | (17,346) | 15,341 | -88.44% | | Cash and cash equivalents and restricted cash at end of period | 30,302 | 45,745 | (15,443) | -33.76% | [Notes to Condensed Consolidated Financial Statements](index=14&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) These notes provide additional information and explanations for the figures presented in BiomX Inc.'s condensed consolidated financial statements [NOTE 1 – GENERAL](index=14&type=section&id=NOTE%201%20%E2%80%93%20GENERAL) BiomX Inc. is a clinical-stage company developing phage cocktails for chronic diseases, primarily cystic fibrosis. The company has not generated revenue to date but believes its current cash is sufficient for over 12 months. It expects to incur further losses and plans to fund operations through future debt/equity issuances, loans, and grants. A corporate restructuring in May 2022 prioritized the cystic fibrosis program and delayed the atopic dermatitis program to extend capital resources - BiomX is developing natural and engineered phage cocktails to target harmful bacteria in chronic diseases, focusing on cystic fibrosis and, to a lesser degree, atopic dermatitis[44](index=44&type=chunk) - The company has not generated revenue from operations and expects current cash and cash equivalents to fund operations for **more than 12 months** from the issuance date of these financial statements[45](index=45&type=chunk) - A corporate restructuring in May 2022 prioritized the cystic fibrosis program and delayed the atopic dermatitis program to extend capital resources[46](index=46&type=chunk) [NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES](index=15&type=section&id=NOTE%202%20%E2%80%93%20SIGNIFICANT%20ACCOUNTING%20POLICIES) The unaudited condensed consolidated financial statements are prepared in accordance with U.S. GAAP, using management estimates and assumptions. The company adopted ASU 2016-13 on January 1, 2023, which did not have a material impact on its financial statements. The potential impact of the COVID-19 pandemic remains uncertain - The financial statements are prepared in accordance with U.S. GAAP for condensed financial information and rely on management's estimates and assumptions[49](index=49&type=chunk)[52](index=52&type=chunk) - The company adopted ASU 2016-13 on January 1, 2023, and concluded it did not have a material impact on its consolidated financial statements[54](index=54&type=chunk) [NOTE 3 – FAIR VALUE OF FINANCIAL INSTRUMENTS](index=15&type=section&id=NOTE%203%20%E2%80%93%20FAIR%20VALUE%20OF%20FINANCIAL%20INSTRUMENTS) The company categorizes financial instruments using a three-level fair value hierarchy. As of March 31, 2023, cash equivalents (money market funds) were Level 1, foreign exchange contracts were Level 2, and contingent consideration was Level 3. The fair value of contingent consideration is based on a probability discounted cash flow analysis with significant unobservable inputs | Financial Instrument (USD in thousands) | March 31, 2023 Fair Value | December 31, 2022 Fair Value | | :------------------------------------ | :------------------------ | :--------------------------- | | **Assets:** | | | | Money market funds (Level 1) | 23,897 | 27,824 | | **Liabilities:** | | | | Contingent consideration (Level 3) | 152 | 148 | | Foreign exchange contracts payable (Level 2) | 95 | 55 | - The fair value of contingent consideration is determined using a probability discounted cash flow analysis, relying on significant unobservable inputs (Level 3)[59](index=59&type=chunk) - The company uses foreign exchange contracts (Level 2) to hedge currency exposure, with outstanding contracts of approximately **$4,647 thousand** (USD to NIS) as of March 31, 2023[60](index=60&type=chunk) [NOTE 4 – OTHER CURRENT ASSETS](index=18&type=section&id=NOTE%204%20%E2%80%93%20OTHER%20CURRENT%20ASSETS) Other current assets primarily consist of prepaid insurance and grants receivables. As of March 31, 2023, total other current assets were $2,632 thousand, a slight increase from $2,587 thousand at December 31, 2022 | Other Current Assets (USD in thousands) | March 31, 2023 | December 31, 2022 | | :------------------------------------ | :------------- | :---------------- | | Government institutions | 47 | 90 | | Prepaid insurance | 1,545 | 1,410 | | Other prepaid expenses | 171 | 84 | | Grants receivables | 853 | 567 | | Other | 16 | 436 | | **Total Other Current Assets** | **2,632** | **2,587** | [NOTE 5 – OTHER ACCOUNTS PAYABLE](index=18&type=section&id=NOTE%205%20%E2%80%93%20OTHER%20ACCOUNTS%20PAYABLE) Other accounts payable increased to $2,956 thousand as of March 31, 2023, from $2,150 thousand at December 31, 2022, primarily driven by an increase in accrued expenses | Other Accounts Payable (USD in thousands) | March 31, 2023 | December 31, 2022 | | :-------------------------------------- | :------------- | :---------------- | | Employees and related institutions | 789 | 800 | | Accrued expenses | 1,803 | 887 | | Government institutions | 156 | 166 | | Deferred income | 114 | 242 | | Other | 94 | 55 | | **Total Other Accounts Payable** | **2,956** | **2,150** | [NOTE 6 – COMMITMENTS AND CONTINGENCIES](index=18&type=section&id=NOTE%206%20%E2%80%93%20COMMITMENTS%20AND%20CONTINGENCIES) BiomX has received significant grants from the Israel Innovation Authority (IIA) for its cystic fibrosis and IBD/PSC programs, totaling approximately $6,960 thousand received through March 31, 2023. Most of these grants are subject to 3-3.5% royalties on future sales, contingent on successful R&D and sales generation. The company also has a research collaboration agreement with Boehringer Ingelheim for IBD, eligible for $1,411 thousand in fees, with $500 thousand received by March 31, 2023 - Through March 31, 2023, BiomX received an aggregate of **$6,960 thousand** in grants from the IIA for various R&D programs, primarily for cystic fibrosis[70](index=70&type=chunk) - IIA grants, excluding the August 2021 program, are subject to **3% to 3.5% royalties** on future sales, contingent on successful R&D and sales generation. As of March 31, 2023, the contingent obligation to the IIA was approximately **$6,640 thousand**[69](index=69&type=chunk)[70](index=70&type=chunk) - A research collaboration agreement with Boehringer Ingelheim for IBD provides for eligible fees totaling **$1,411 thousand**, with **$500 thousand** received by March 31, 2023[71](index=71&type=chunk) [NOTE 7 – LONG-TERM DEBT](index=20&type=section&id=NOTE%207%20%E2%80%93%20LONG-TERM%20DEBT) BiomX has a Loan and Security Agreement with Hercules Capital, Inc. for a $30,000 thousand term loan facility, of which $15,000 thousand was advanced. Subsequent tranches were not reached. The loan accrues interest at a rate based on the Prime Rate plus 5.70% (or 8.95% minimum), with an effective interest rate of 16.79% as of March 31, 2023. Repayments of principal and interest began March 1, 2023, through September 1, 2025. The loan is secured by intellectual property and includes a liquidity covenant requiring a minimum cash balance of $5,000 thousand - BiomX has a **$15,000 thousand** term loan outstanding from Hercules Capital, Inc., with additional tranches of **$10,000 thousand** and **$5,000 thousand** not reached or expected to be reached[73](index=73&type=chunk) - The interest rate is the greater of Prime Rate + **5.70%** or **8.95%**, resulting in an effective interest rate of **16.79%** as of March 31, 2023[75](index=75&type=chunk) Future Principal Payments (USD in thousands) | Future Principal Payments (USD in thousands) | March 31, 2023 | | :----------------------------------------- | :------------- | | 2023 | $3,842 | | 2024 | $5,785 | | 2025 | $4,954 | | **Total principal payments** | **$14,581** | | Unamortized discount and debt issuance costs | ($59) | | **Total future principal payments** | **$14,522** | | Current portion of long-term debt | ($5,216) | | **Long-term debt, net** | **$9,306** | - The loan is secured by substantially all of the company's intellectual property and includes a liquidity covenant requiring a minimum aggregate compensating cash balance of **$5,000 thousand**[78](index=78&type=chunk) [NOTE 8 – STOCKHOLDERS EQUITY](index=22&type=section&id=NOTE%208%20%E2%80%93%20STOCKHOLDERS%20EQUITY) Stockholders' equity details include share capital from a Private Investment in Public Equity (PIPE) financing, an At-the-market Sales Agreement, and agreements with Maruho and the Cystic Fibrosis Foundation. The PIPE's first closing in February 2023 generated $1,293 thousand net proceeds. The company also has various outstanding warrants and stock options. Stock-based compensation expenses for Q1 2023 were $175 thousand - The first closing of a Private Investment in Public Equity (PIPE) financing on February 27, 2023, resulted in the issuance of **3,199,491 shares of Common Stock** and **2,776,428 pre-funded warrants**, generating net proceeds of **$1,293 thousand**[82](index=82&type=chunk) Warrant Details | Warrant Type | Issuance Date | Expiration Date | Exercise Price Per Share | Number of Shares Underlying Warrants | | :--------------------------- | :------------------ | :---------------- | :----------------------- | :----------------------------------- | | Private Placement Warrants | Dec 13, 2018 | Dec 13, 2023 | $11.50 | 2,900,000 | | Public Warrants | Dec 13, 2018 | Oct 28, 2024 | $11.50 | 3,500,000 | | 2021 Registered Direct Offering Warrants | July 28, 2021 | Jan 28, 2027 | $5.00 | 2,812,501 | | Pre-Funded Warrants | Feb 27, 2023 | No expiration date | $0.001 | 2,776,428 | | **Total Outstanding Warrants** | | | | **11,988,929** | Stock-based Compensation Expenses (USD in thousands) | Stock-based Compensation Expenses (USD in thousands) | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | | :--------------------------------------------------- | :-------------------------------- | :-------------------------------- | | Research and development expenses, net | 87 | 258 | | General and administrative | 88 | 357 | | **Total** | **175** | **615** | [NOTE 9 – BASIC AND DILUTED LOSS PER SHARE](index=25&type=section&id=NOTE%209%20%E2%80%93%20BASIC%20AND%20DILUTED%20LOSS%20PER%20SHARE) Basic loss per share is calculated based on net loss and weighted average common shares outstanding. Diluted loss per share includes potential common shares when dilutive; however, for the three months ended March 31, 2023, 6,114,600 options, 9,215,475 warrants, and 4,000,000 contingent shares were anti-dilutive and thus excluded. Fully vested Pre-Funded Warrants were included - Basic and diluted loss per share for Q1 2023 was **$0.20**, based on a net loss of **$6,361 thousand** and **32,125,227 weighted average shares outstanding**[25](index=25&type=chunk) - Outstanding stock options, warrants, and contingent shares were excluded from diluted EPS calculation for Q1 2023 because their effect would be anti-dilutive[95](index=95&type=chunk) [NOTE 10 – SUBSEQUENT EVENTS](index=25&type=section&id=NOTE%2010%20%E2%80%93%20SUBSEQUENT%20EVENTS) Subsequent to March 31, 2023, BiomX received $700 thousand from Boehringer Ingelheim, final IIA payments of $275 thousand for March 2021 programs, and first IIA payments of $328 thousand for March 2023 programs. The second closing of the PIPE financing was completed on May 4, 2023, following stockholder approval, issuing 24,632,243 securities for approximately $6,000 thousand in gross proceeds - On April 11, 2023, the company received **$700 thousand** from Boehringer Ingelheim as part of the research collaboration agreement[96](index=96&type=chunk) - On April 18, 2023, the company received final payments of approximately **$275 thousand** from the IIA for March 2021 programs and first payments of approximately **$328 thousand** for March 2023 programs[96](index=96&type=chunk) - The second closing of the PIPE financing occurred on May 4, 2023, after stockholder approval, resulting in the issuance of **24,632,243 securities** for approximately **$6,000 thousand** in gross proceeds[97](index=97&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=27&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section provides management's perspective on BiomX Inc.'s financial condition and results of operations for the three months ended March 31, 2023. It covers the company's business overview, clinical and pre-clinical development progress, a detailed comparison of financial results, liquidity and capital resources, cash flow analysis, and future outlook. The discussion highlights the corporate restructuring, prioritization of the CF program, and the need for future financing [General](index=27&type=section&id=General) BiomX is a clinical-stage company utilizing natural and engineered phage technologies to target harmful bacteria in chronic diseases, with a primary focus on cystic fibrosis. Its proprietary BOLT platform enables agile development of phage-based therapies. A corporate restructuring in May 2022 prioritized the CF program and delayed the atopic dermatitis program, involving a 42% reduction in workforce to extend capital resources - BiomX is a clinical-stage company developing phage technologies to target specific harmful bacteria associated with chronic diseases, such as cystic fibrosis (CF)[100](index=100&type=chunk) - The company utilizes its proprietary BacteriOphage Lead to Treatment (BOLT) platform for the agile and efficient development of natural or engineered phage combinations[101](index=101&type=chunk) - A corporate restructuring in May 2022 prioritized the CF program, delayed the atopic dermatitis (AD) program, and included a layoff of approximately **42% of employees** to extend capital resources[103](index=103&type=chunk) [Clinical and Pre-Clinical Developments](index=27&type=section&id=Clinical%20and%20Pre-Clinical%20Developments) BiomX reported positive Part 1 results from its Phase 1b/2a trial for BX004 in cystic fibrosis, showing no safety events, a significant reduction in P. aeruginosa, and no emerging resistance. Part 2 results are expected in Q3 2023. For atopic dermatitis, BX005 received FDA IND approval, with preclinical activities ongoing. Programs for Inflammatory Bowel Disease/Primary Sclerosing Cholangitis (BX003) and Colorectal Cancer are currently on hold due to resource prioritization. COVID-19 has not materially impacted operations to date, but future uncertainty remains [Cystic Fibrosis (BX004)](index=27&type=section&id=Cystic%20Fibrosis) BiomX's BX004 for cystic fibrosis showed positive Part 1 Phase 1b/2a trial results, with no safety events and significant P. aeruginosa reduction; Part 2 results are anticipated in Q3 2023 - BX004, a therapeutic phage product candidate for chronic pulmonary infections caused by Pseudomonas aeruginosa in CF patients, showed positive Part 1 results in its Phase 1b/2a trial[104](index=104&type=chunk)[106](index=106&type=chunk) - Part 1 results indicated no safety events, a mean P. aeruginosa CFU reduction of **-1.42 log** (vs. **-0.28 log** for placebo), phage detection up to Day 15, and no emerging resistance[106](index=106&type=chunk) - Results from Part 2 of the Phase 1b/2a trial, evaluating safety and efficacy in **24 CF patients**, are expected in the **third quarter of 2023**[107](index=107&type=chunk) [Atopic Dermatitis (BX005)](index=29&type=section&id=Atopic%20Dermatitis) BX005, a topical phage candidate for atopic dermatitis, demonstrated over 90% S. aureus eradication in preclinical studies, with FDA IND approval received and clinical trial timelines under evaluation - BX005 is a topical phage product candidate targeting Staphylococcus aureus, associated with atopic dermatitis, and was shown to eradicate **over 90% of S. aureus strains** in preclinical studies[109](index=109&type=chunk) - The FDA approved the investigational new drug application for BX005 on April 8, 2022, and preclinical activities are ongoing to evaluate timelines for a clinical trial[110](index=110&type=chunk)[111](index=111&type=chunk) [Programs on hold](index=29&type=section&id=Programs%20on%20hold) Development efforts for BX003 (IBD/PSC) and the Colorectal Cancer program were paused in November 2021 to reallocate resources towards cystic fibrosis and atopic dermatitis programs - Development efforts for BX003 (Inflammatory Bowel Disease and Primary Sclerosing Cholangitis) and the Colorectal Cancer program were paused on November 15, 2021, to prioritize resources for CF and AD programs[113](index=113&type=chunk)[114](index=114&type=chunk) [COVID-19 Impact](index=29&type=section&id=COVID-19) As of May 11, 2023, COVID-19 has not materially impacted operations, but its potential future effects on R&D and financial condition remain uncertain - As of May 11, 2023, COVID-19 has not had a material impact on the company's results of operations, but uncertainty remains regarding its potential future impact on R&D activities and financial condition[114](index=114&type=chunk) [Consolidated Results of Operations](index=30&type=section&id=Consolidated%20Results%20of%20Operations) For the three months ended March 31, 2023, BiomX reported a reduced net loss of $6.4 million, down from $8.2 million in the prior year. This improvement was driven by a 6% decrease in R&D expenses (to $4.6 million) and a 36% decrease in General and Administrative expenses (to $1.6 million), primarily due to workforce reduction and delayed AD program activities. Finance income significantly increased by 276% due to rising interest rates and USD appreciation | Metric (USD in thousands) | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | Change | % Change | | :------------------------ | :-------------------------------- | :-------------------------------- | :----- | :------- | | R&D expenses, net | 4,564 | 4,929 | (365) | -7.40% | | General and administrative expenses | 1,644 | 2,477 | (833) | -33.63% | | Operating loss | 6,208 | 7,786 | (1,578) | -20.27% | | Interest expenses | 565 | 461 | 104 | 22.56% | | Finance income, net | (327) | (87) | (240) | 275.86% | | Net loss | 6,361 | 8,169 | (1,808) | -22.13% | | Basic and diluted loss per share | 0.20 | 0.27 | (0.07) | -25.93% | - The decrease in R&D expenses was primarily due to reduced salaries, related expenses, and stock-based compensation from workforce reduction and delayed AD program activities, partially offset by CF clinical trial expenses[115](index=115&type=chunk) - The increase in finance income, net, was primarily due to rising interest rates leading to higher interest income and the appreciation of the U.S. dollar against the NIS[119](index=119&type=chunk) [Liquidity and Capital Resources](index=31&type=section&id=Liquidity%20and%20Capital%20Resources) BiomX anticipates its current cash and cash equivalents, along with short-term deposits, will fund operations until Q3 2024. The company has implemented expense reductions, including a corporate restructuring and subleasing office space. Future funding will likely be sought through public or private equity, debt financings, loans, and grants to support ongoing operations and potential expansion of development plans - The company believes its cash and cash equivalents and short-term deposits are sufficient to meet working capital and capital expenditure requirements until into the **third quarter of 2024**[121](index=121&type=chunk) - Operating plans have been revised to reduce expenses, including a corporate restructuring that significantly reduced employee-related costs and subleasing a portion of office space[121](index=121&type=chunk) - Future additional funds will likely be raised through public or private equity, debt financings, loans, governmental or other grants, or collaborative agreements[121](index=121&type=chunk) [Cash Flows](index=31&type=section&id=Cash%20Flows) In Q1 2023, net cash used in operating activities decreased to $5.0 million from $7.4 million in Q1 2022, primarily due to a lower net loss and changes in operating assets/liabilities. Investing activities provided $2.0 million in cash, a significant shift from $10.0 million used in Q1 2022, mainly from proceeds from short-term deposits. Financing activities provided $1.1 million, largely due to the first closing of the PIPE, compared to $37 thousand in Q1 2022 | Cash Flow Activity (USD in thousands) | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | | :------------------------------------ | :-------------------------------- | :-------------------------------- | | Net cash used in operating activities | (5,045) | (7,363) | | Net cash provided by (used in) investing activities | 1,990 | (10,020) | | Net cash provided by financing activities | 1,050 | 37 | - Net cash used in operating activities decreased by **$2.3 million**, primarily due to a lower net loss and favorable changes in operating assets and liabilities[123](index=123&type=chunk)[124](index=124&type=chunk) - Net cash provided by investing activities in Q1 2023 was mainly from **$2.0 million** in proceeds from short-term deposits, contrasting with **$10.0 million** used for investments in Q1 2022[125](index=125&type=chunk) - Net cash provided by financing activities increased significantly due to **$1.5 million** from the first closing of the PIPE, partially offset by long-term debt repayment[127](index=127&type=chunk) [Outlook](index=34&type=section&id=Outlook) BiomX has an accumulated deficit of $143.2 million and does not expect significant revenue in the next twelve months. With existing liquidity and additional proceeds from the PIPE's second closing, the company projects sufficient funds until Q3 2024. It plans to secure further capital through equity, debt, loans, and grants to support ongoing R&D and potential new product candidates - BiomX has an accumulated deficit of **$143.2 million** and does not expect to generate significant revenues from product sales in the next twelve months[133](index=133&type=chunk) - The company's liquidity resources, including cash, cash equivalents, short-term deposits, restricted cash (**$30.3 million** as of March 31, 2023), and an additional **$6 million** from the PIPE's second closing, are expected to fund operations until **Q3 2024**[133](index=133&type=chunk) - Future funding will be sought through public or private equity, debt securities, loans, and additional grants to support ongoing R&D and development of new product candidates[134](index=134&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=34&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, BiomX Inc. is not required to provide disclosures under this item - As a smaller reporting company, BiomX Inc. is exempt from providing disclosures under Item 3[136](index=136&type=chunk) [Item 4. Controls and Procedures](index=34&type=section&id=Item%204.%20Controls%20and%20Procedures) BiomX Inc.'s management, including its principal executive and financial officers, concluded that the company's disclosure controls and procedures were effective as of March 31, 2023. There have been no material changes in internal control over financial reporting during the quarter - Management concluded that the company's disclosure controls and procedures were effective as of March 31, 2023[138](index=138&type=chunk) - There were no material changes in internal control over financial reporting during the quarter ended March 31, 2023[139](index=139&type=chunk) [PART II - OTHER INFORMATION](index=35&type=section&id=Part%20II.%20Other%20Information) This section lists the exhibits filed with BiomX Inc.'s Form 10-Q, including corporate governance documents and XBRL data files [Item 6. Exhibits](index=35&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including the company's Amended and Restated Certificate of Incorporation, Bylaws, Form of Indemnification Agreement, certifications from principal officers, and Inline XBRL documents - Exhibits include the Composite Copy of Amended and Restated Certificate of Incorporation, Amended and Restated Bylaws, Form of Indemnification Agreement, and certifications of principal executive and financial officers[141](index=141&type=chunk) - The filing also includes Inline XBRL Instance Document, Taxonomy Extension Schema Document, Calculation Linkbase Document, Definition Linkbase Document, Label Linkbase Document, Presentation Linkbase Document, and Cover Page Interactive Data File[141](index=141&type=chunk) [PART III - SIGNATURES](index=36&type=section&id=Part%20III.%20Signatures) This section contains the official signatures of BiomX Inc.'s principal executive and financial officers, certifying the accuracy of the Form 10-Q filing [Signatures](index=36&type=section&id=Signatures) The report is duly signed on behalf of BiomX Inc. by Jonathan Solomon, Chief Executive Officer, and Marina Wolfson, Chief Financial Officer and Principal Accounting Officer, on May 15, 2023 - The report was signed by Jonathan Solomon, Chief Executive Officer, and Marina Wolfson, Chief Financial Officer and Principal Accounting Officer, on May 15, 2023[147](index=147&type=chunk)

BiomX Inc. (NYSE:PHGE) Q1 2023 Results Conference Call May 15, 2023 8:00 AM ET Company Participants Marina Wolfson - CFO Jonathan Solomon - CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Michael Higgins - Ladenburg Thalmann Operator Good morning, and welcome to the BiomX First Quarter 2023 Financial Results and Corporate Update Conference Call. Currently, all participants are in a listen-only mode. There will be a question-and-answer session at the end of this call. I would now like to tur ...

BiomX Inc. (NYSE:PHGE) Q4 2022 Earnings Conference Call March 29, 2023 8:00 AM ET Company Participants Marina Wolfson – Chief Financial Officer Jonathan Solomon – Chief Executive Officer Conference Call Participants Joe Pantginis – H.C. Wainwright Operator Good morning, and welcome to the BiomX Full Year 2022 Financial Results and Corporate Update Conference Call. Currently, all participants are in a listen-only mode. There will be a question-and-answer session at the end of this call. I would now like to t ...

Product Development and Trials - The company is developing phage-based therapies targeting harmful bacteria associated with chronic diseases, utilizing a proprietary platform named BOLT [21]. - BX004, targeting Pseudomonas aeruginosa in cystic fibrosis patients, showed a mean reduction of -1.42 log CFU at Day 15 compared to baseline, with no safety events reported [28]. - The Phase 1b/2a trial for BX004 is ongoing, with results from Part 2 expected in Q3 2023, involving 24 CF patients in a 2:1 treatment to placebo ratio [29]. - BX005, targeting Staphylococcus aureus for atopic dermatitis, has shown over 90% efficacy in eradicating antibiotic-resistant strains in preclinical studies [31]. - The FDA approved the IND application for BX005 in April 2022, and the company is evaluating timelines for clinical trials [33]. - The company has paused development of BX003 and CRC programs to prioritize resources for CF and atopic dermatitis initiatives [36][39]. - The company is developing product candidates using phage technology, which has not yet received regulatory approval in the US or EU [192]. - Clinical testing is required to demonstrate safety and efficacy, which can be expensive and time-consuming, particularly for genetically modified phage candidates [196]. - Regulatory approvals for therapeutic indications are expensive and can take many years, with the potential for delays due to additional required studies [204]. - The FDA may require an Advisory Committee to review safety and efficacy data, which could impact approval chances [206]. - Regulatory authorities may approve product candidates for fewer therapeutic indications than requested, affecting commercialization prospects [208]. Financials and Funding - The company received a total of $5 million from the Cystic Fibrosis Foundation to support BX004 development, with $2 million coming after positive trial results [30]. - The company had cash, cash equivalents, and restricted cash of $32.3 million as of December 31, 2022, and anticipates needing to raise additional capital to support operations and product development activities [184]. - In February 2023, the company closed the first part of a PIPE financing, raising approximately $1.5 million in gross proceeds, with a second closing expected to raise an additional $6 million [184]. - The company has a term loan agreement with Hercules for up to $30 million, of which $15 million has been received, but the second tranche of $10 million was not available due to unmet milestones [190]. - The company is obligated to pay a non-refundable license fee of $10,000 per year under the Yeda 2015 License Agreement, along with approximately $2.0 million contributed to the research budget [158]. - Under the Exclusive Patent License Agreement with JSR, the company agreed to pay annual fees ranging from $15,000 to $25,000 and milestone payments up to $3.2 million [164]. - The company faces significant uncertainty regarding the coverage and reimbursement status of products once regulatory approval is obtained [150]. - The company has never generated any revenue from product sales and may never achieve profitability [211]. - The ability to generate meaningful revenue depends on successfully completing development and meeting regulatory requirements [211]. - Significant costs are anticipated for commercializing any approved product, which may require additional funding [212]. Regulatory Environment - The FDA regulates the approval process for new drugs, requiring extensive data on quality, safety, and efficacy before marketing [71]. - The FDA may suspend or terminate clinical trials if patients are exposed to unacceptable health risks [79]. - Phase 1 clinical trials assess metabolism, pharmacologic action, and safety with a small number of participants [81]. - Phase 3 clinical trials involve a large number of patients to demonstrate product effectiveness and safety [81]. - The FDA has 10 months to complete its initial review of a BLA, or 6 months for priority reviews [83]. - Orphan drug designation provides financial incentives and exclusivity for seven years post-approval [87]. - Fast-track designation expedites the review process for drugs addressing serious conditions [88]. - Products may receive accelerated approval if they show effects on surrogate endpoints likely to predict clinical benefit [89]. - Pediatric studies are required to assess safety and efficacy for all relevant pediatric subpopulations [93]. - Manufacturers must comply with cGMP regulations to ensure product quality and safety [96]. - The Biologics Price Competition and Innovation Act allows for an abbreviated approval pathway for biosimilars [98]. - The company is subject to 12 years of data exclusivity for reference biological products from the first licensure date, with a four-year waiting period for biosimilar applications [100]. - Pediatric exclusivity can add six months to existing regulatory exclusivity periods if a pediatric trial is completed as per FDA's request [101]. - Companion diagnostics are utilized to identify patients likely to benefit from therapeutic products, requiring FDA clearance or approval prior to commercialization [102]. - The marketing authorization process in the European Union can take up to 210 days, with a maximum timeframe for evaluation [110]. - Orphan drug designation in the EU provides ten years of market exclusivity post-approval, which can be reduced to six years if criteria are no longer met [115]. - Conditional marketing authorizations in the EU allow for earlier market access based on incomplete clinical data, valid for one year and renewable [118]. - The EMA's PRIME status supports the development and accelerates the approval of innovative medicinal products addressing unmet medical needs [119]. - Pediatric data submission is mandatory for new active substances or new therapeutic indications, with a pediatric investigation plan required [121]. - The company must comply with various foreign regulatory requirements for clinical trials and product approvals, which may differ significantly from U.S. regulations [104]. - The approval process for medicinal products varies by country and may involve additional testing compared to U.S. standards [106]. - The company may apply for a Supplementary Protection Certificate (SPC) to extend patent life beyond current expiration dates, depending on clinical trial lengths and other factors [128]. - A medicinal product with a new active substance is granted eight years of data exclusivity followed by two years of market protection, preventing generics from entering the market during this period [129]. - Biosimilars can be approved through an abbreviated pathway after the expiration of the eight-year data exclusivity period and may be marketed after a 10 or 11-year market protection period [130]. - Market exclusivity for orphan status products prevents the EMA or national authorities from granting another marketing authorization for a similar product for ten years from approval [131]. - Completion of a Pediatric Investigation Plan (PIP) can lead to a pediatric reward, which may include a six-month extension of SPC or two additional years of market exclusivity for orphan products [132]. Competition and Market Dynamics - The biotechnology and pharmaceutical industries are characterized by strong competition, with key factors including efficacy, safety, and intellectual property protection [66]. - The company faces competition from larger pharmaceutical companies and other biotechnology firms with greater resources and experience [67]. - The commercial success of drug candidates will depend on market acceptance and physician adoption [214]. - High titers for specific phage cocktails necessary for testing may be difficult and time-consuming to achieve [216]. - Preclinical study results may not predict outcomes in clinical trials, leading to potential setbacks [217]. - Regulatory approval processes are extensive and could delay or prevent marketing of product candidates [220]. Operational Challenges - The company plans to continue prioritizing its ongoing CF program while implementing a 50% reduction in personnel as part of its corporate restructuring plan announced in May 2022 [172]. - As of December 31, 2022, the company employed 54 full-time and 11 part-time employees, with 50 engaged in research and development and clinical activities [171]. - The company has not laid off any employees due to the COVID-19 pandemic and has implemented safety measures to ensure employee well-being [173]. - The company is focused on expanding its clinical product pipeline and anticipates significant expenses related to research and development and clinical trials in the foreseeable future [182]. - The company may seek funds through collaborations that could require relinquishing rights to product candidates, potentially affecting future development [184]. - The company faces risks related to market volatility and economic conditions that could adversely affect its ability to raise funds and impact its stock price [186]. - The Hercules Loan Agreement includes affirmative covenants requiring the company to maintain legal existence and deliver financial reports, and negative covenants restricting additional indebtedness and mergers [191]. - The ongoing COVID-19 pandemic has caused significant disruptions, including delays in patient enrollment and clinical trial operations [197]. - The complexity of genetically modified phage therapy may extend the time required for regulatory approval [220]. Legal and Compliance Issues - The company is subject to various federal and state laws targeting fraud and abuse in the healthcare industry, which may impact business operations [134]. - Violations of fraud and abuse laws may result in significant penalties, including fines, imprisonment, and exclusion from federal healthcare programs [138]. - The company must comply with environmental protection laws, which govern the handling and disposal of hazardous substances used in operations [143]. - The U.S. Foreign Corrupt Practices Act prohibits bribery of foreign officials to obtain or retain business, with similar laws in other countries [144]. - The Affordable Care Act (ACA) has led to increased Medicaid rebates and new methodologies for calculating rebates for certain drugs, impacting reimbursement rates [145]. - The Budget Control Act of 2011 and the Bipartisan Budget Act of 2015 resulted in a 2% reduction in Medicare payments to providers, effective through 2030 [148]. - The American Rescue Plan Act of 2021 eliminates the statutory Medicaid drug rebate cap starting January 1, 2024, potentially affecting drug pricing [146]. - The Inflation Reduction Act allows Medicare to negotiate drug prices for high-expenditure, single-source drugs, impacting pharmaceutical pricing strategies [148].

Financial Data and Key Metrics Changes - As of September 30, 2022, cash balance and short-term deposits were $41.5 million, down from $63.1 million as of December 31, 2021, primarily due to net cash used in operating activities [13] - Net loss for Q3 2022 was $6.8 million, compared to $10 million for the same period in 2021 [16] - Net cash used in operating activities for the nine months ended September 30, 2022, was $21.9 million, compared to $18.5 million for the same period in 2021 [16] Business Line Data and Key Metrics Changes - Research and development expenses were $3.5 million for Q3 2022, down from $6.6 million for the same period in 2021, reflecting a decrease in salaries and related expenses due to corporate restructuring and paused development of certain product candidates [14] - General and administrative expenses were $2.6 million for Q3 2022, compared to $2.8 million for the same period in 2021, also reflecting a decrease in salaries and related expenses due to corporate restructuring [15] Market Data and Key Metrics Changes - The company is focused on the ongoing Phase Ib/IIa trial of BX004 in cystic fibrosis, with an expected completion of enrollment in Part 1 by year-end 2022 and results anticipated in Q1 2023 [9][10] Company Strategy and Development Direction - The company aims to advance the BX004 program as a treatment for cystic fibrosis patients with chronic respiratory infections caused by Pseudomonas aeruginosa, emphasizing the importance of ongoing research and development efforts [10][18] - The company is also pursuing preclinical activities for BX005 in atopic dermatitis, working with Maruho on formulation and planning for future clinical trials [30] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in patient enrollment due to COVID-19 and the holiday season but noted an uptick in enrollment trends due to improved mechanisms and increased site numbers [22][23] - The company remains optimistic about the future of phage therapy and its potential impact on cystic fibrosis treatment [27][34] Other Important Information - The company estimates that existing cash, cash equivalents, and short-term deposits are sufficient to fund its current operating plan at least through mid-2024 [16] Q&A Session Summary Question: Can you define the enrollment-enhancing mechanisms discussed? - Management noted initial enrollment was slower than anticipated due to COVID-19 and holidays, but they have implemented mechanisms to improve interaction with CROs and increased the number of sites [22][23] Question: What is the real-world impact from the holidays on scheduling and analyses? - Management indicated that the holidays had some impact, but they are optimistic about the recent uptick in enrollment [22] Question: Were there any amendments made to the trial? - Management confirmed no significant amendments were made, focusing instead on adding additional sites [26] Question: Is the atopic dermatitis program still a priority? - Management stated that while the focus is currently on cystic fibrosis, they are working with Maruho on the atopic dermatitis program and will reassess once progress is made [30]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38762 BiomX Inc. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 82-3364020 | | --- | --- | | (State or other juris ...

Financial Data and Key Metrics Changes - As of June 30, 2022, cash balance and short-term deposits were $46.7 million, down from $63.1 million as of December 31, 2021, primarily due to net cash used in operating activities [29] - Research and development expenses net were $4.6 million for the three months ended June 30, 2022, compared to $3.8 million for the same period in 2021 [30] - General and administrative expenses were $2.4 million for the three months ended June 30, 2022, down from $3.1 million for the same period in 2021 [31] - Net cash used in operating activities was $16.4 million for the six months ended June 30, 2022, compared to $12.8 million for the same period in 2021 [32] Business Line Data and Key Metrics Changes - The cystic fibrosis program, specifically BX004, has dosed the first two patients in its Phase 1b/2a study, marking a significant milestone [8][10] - The company has paused the development of BX003 and discontinued BX001, which has affected R&D expenses [30] Market Data and Key Metrics Changes - The opportunity to address lung infections in cystic fibrosis remains substantial, with approximately 70,000 to 80,000 patients in the US and EU, and over 60% of adults with cystic fibrosis infected with Pseudomonas aeruginosa [12] Company Strategy and Development Direction - The company is focusing on advancing the BX004 program as a clinical development priority, addressing the unmet medical need in cystic fibrosis [21] - A second collaboration with Boehringer Ingelheim was announced to identify biomarkers for a pathogenic bacterium associated with inflammatory bowel disease [22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of phage therapy for treating lung infections in cystic fibrosis, highlighting the need for new therapies [33] - The company aims to generate solid clinical data to rebuild investor enthusiasm and is preparing for initial clinical results for BX004 [33] Other Important Information - A restructuring was completed to extend the company's cash runway until at least mid-2024 [27] - The company has published research supporting its inflammatory bowel disease program and technology platform [23][24] Q&A Session Summary Question: Current supply and manufacturing efficiencies - The company has in-house manufacturing to control the supply chain and has capacity to support Phase 2 needs [34] Question: Predictability factors for infections with Trikafta - There is limited data, but initial findings suggest a drop in Pseudomonas levels followed by a resurgence [43] Question: Thoughts on the upcoming FDA panel for another microbiome company - There is a growing comfort in the approval process for microbiome products, and surrogate endpoints may expedite approvals [46][48] Question: Enrollment of patients for BX005 - The study has not started yet, and the focus remains on BX004 due to restructuring [57] Question: Plans to broaden BX003 - BX003 is not prioritized in the next 12 months, but a broader cocktail is being considered [60] Question: Use of microbiome as a screener for patients - The collaboration with Boehringer Ingelheim aims to identify biomarkers to better stratify patients for treatment [62]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38762 BiomX Inc. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 82-3364020 | | --- | --- | | (State or other jurisdicti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Commission file number: 001-38762 BiomX Inc. FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact Name of Registrant as Specified in Its Charter) | Delaware | 82-3364020 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | inco ...